{"id":"W2087619366","doi":"10.1158/0008-5472.sabcs13-ot3-2-08","title":"Abstract OT3-2-08: A phase 2 single-arm study of the clinical activity and safety of enzalutamide in patients with advanced androgen receptor-positive triple-negative breast cancer","year":2013,"lang":"en","type":"article","venue":"Cancer Research","topic":"Estrogen and related hormone effects","field":"Biochemistry, Genetics and Molecular Biology","cited_by":5,"is_retracted":false,"has_abstract":true,"ca_institutions":"Sunnybrook Health Science Centre","funders":"","keywords":"Enzalutamide; Androgen receptor; Triple-negative breast cancer; Medicine; Breast cancer; Bicalutamide; Internal medicine; Oncology; Clinical endpoint; Estrogen receptor; Cancer; Clinical trial; Cancer research; Prostate cancer","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.001332383,0.001534377,0.002067624,0.0003955891,0.0003511692,0.0009778794,0.0007959972,0.001194783,0.00512325],"category_scores_gemma":[0.0008069075,0.0005110549,0.001052915,0.0004184387,0.0008968013,0.0008435167,0.000273706,0.00248315,0.0008393016],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0008412448,"about_ca_system_score_gemma":0.001839491,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.001443845,"about_ca_topic_score_gemma":0.003864228,"domain_scores_codex":[0.9996912,0.0001454165,0.00001541767,0.00004255438,0.00002946964,0.00007595948],"domain_scores_gemma":[0.9995145,0.00008310306,0.00009041484,0.00003663703,0.00003468612,0.0002407496],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"randomized_trial","study_design_gemma":"nonrandomized_trial","study_design_scores_codex":[0.8425014,0.04742854,0.002251119,0.001017547,0.0008706697,0.0001470238,0.0001734326,0.001714783,0.03680906,0.0002745803,0.003651174,0.06316059],"study_design_scores_gemma":[0.6351826,0.3554334,0.004597656,0.00003314929,0.0002667338,0.0001244822,0.00003955607,0.001039062,0.001839141,0.0001410018,0.001276858,0.00002642577],"study_design_candidate":"nonrandomized_trial","study_design_consensus":null,"genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9924349,0.001344079,0.0005048114,0.0003204523,0.0001056923,0.002503923,0.001012966,0.0001642402,0.001609032],"genre_scores_gemma":[0.9878671,0.001282914,0.00163515,0.0007694568,0.0001654725,0.003239199,0.001430565,0.00004528084,0.003564749],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.00512325,"threshold_uncertainty_score":0.01713902,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.0245253692138119,"score_gpt":0.3701040258697162,"score_spread":0.3455786566559044,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}